MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Calithera Biosciences Cash Conversion Cycle 2011-2026 | CALA
Annual Cash Conversion Cycle Calithera Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 28.8 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.8 | 28.8 | 28.8 |
Quarterly Cash Conversion Cycle Calithera Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 0.16 | 15.8 | - | - | - | - | - | - | - | - | - | - | 8.19 | 10.7 | 27.6 | 14.4 | 14.4 | 14.4 | 12.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.6 | 0.16 | 13.1 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.36 | -1.64 % | $ 2.57 B |  USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.81 | -4.23 % | $ 4.42 M |  China |
 |
Axsome Therapeutics
AXSM
|
-256 | $ 164.64 | -1.05 % | $ 8.19 B | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.7 | -3.27 % | $ 1.11 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Certara
CERT
|
81.8 | $ 7.28 | 3.19 % | $ 1.17 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-48.2 | $ 1.01 | -0.49 % | $ 74.1 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
120 | $ 23.89 | 0.04 % | $ 2.92 B | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-6 K | $ 3.22 | -3.59 % | $ 1.15 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
735 | $ 28.92 | -0.96 % | $ 1.68 B | USA |
 |
Champions Oncology
CSBR
|
1.94 | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
-32.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-15.9 | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-839 | $ 3.68 | -3.16 % | $ 116 M |  France |
 |
Alector
ALEC
|
-13.8 | $ 2.13 | -3.62 % | $ 219 M | USA |
 |
Altimmune
ALT
|
15.1 K | $ 4.25 | 2.04 % | $ 302 M | USA |
 |
Teligent, Inc.
TLGT
|
120 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
139 | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
213 | $ 14.2 | 1.9 % | $ 5.89 B |  Irlanda |